Genmab A/S (OTCMKTS:GNMSF) Share Price Passes Below 200-Day Moving Average – Should You Sell?

Shares of Genmab A/S (OTCMKTS:GNMSF) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $296.74 and traded as low as $232.3401. Genmab A/S shares last traded at $232.3401, with a volume of 34 shares traded.

Genmab A/S Stock Down 7.6%

The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87. The firm’s 50 day simple moving average is $267.58 and its 200-day simple moving average is $296.74. The stock has a market capitalization of $14.31 billion, a price-to-earnings ratio of 17.52 and a beta of 0.81.

About Genmab A/S

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.